Drugs Not ‘On Radar’ For Medicare Coverage Review, Official Says
This article was originally published in RPM Report
Executive Summary
The director of Medicare’s coverage and analysis group says that, at the moment, no biopharma products are being considered for a national coverage determination. Another official says Medicare cannot use comparative effectiveness data in making reimbursement decisions.